Celyad Oncology Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 11, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Cap	11	8	29	16	11	79
Market Cap Growth	-34.36%	-74.20%	82.56%	41.33%	-85.61%	-13.96%
Enterprise Value	9.75	6.52	31.04	15.08	4.26	58.24
Last Close Price	0.27	0.17	0.71	0.39	0.51	3.52
PE Ratio	14.22	9.44	-	-	-	-
PS Ratio	545.67	362.36	158.59	158.40	-	-
PB Ratio	4.70	3.12	57.72	2.56	2.65	1.82
P/TBV Ratio	4.77	3.01	278.27	1.70	3.31	7.34
EV/Sales Ratio	-	310.60	166.86	147.86	-	-
EV/EBITDA Ratio	9.26	6.19	-	-	-	-
EV/EBIT Ratio	11.07	7.40	-	-	-	-
Debt / Equity Ratio	-	0	9.70	0.86	1.09	0.17
Debt / EBITDA Ratio	0.59	0.59	-	-	-	-
Net Debt / Equity Ratio	-0.45	-0.45	3.01	-0.17	-1.66	-0.48
Net Debt / EBITDA Ratio	-1.03	-1.03	-0.28	0.14	0.18	0.85
Net Debt / FCF Ratio	0.16	0.16	-0.27	0.07	0.26	0.79
Asset Turnover	0.00	0.00	0.01	0.01	0	0
Inventory Turnover	0.04	0.04	0.06	-	-	-
Quick Ratio	1.35	1.35	1.76	3.31	1.30	2.32
Current Ratio	1.92	1.92	2.29	3.79	1.42	2.48
Return on Equity (ROE)	56.33%	56.33%	-170.92%	-159.08%	-170.72%	-71.05%
Return on Assets (ROA)	12.39%	12.39%	-44.70%	-47.33%	-81.86%	-36.13%
Return on Invested Capital (ROIC)	65.31%	51.84%	-160.96%	-716.84%	-415.95%	-118.69%
Return on Capital Employed (ROCE)	18.43%	18.43%	-57.34%	-74.71%	-108.36%	-43.85%
Earnings Yield	7.24%	10.59%	-	-	-	-
Buyback Yield / Dilution	-11.68%	-3.26%	-61.06%	-13.84%	-44.80%	-11.92%
Total Shareholder Return	-11.68%	-3.26%	-61.06%	-13.84%	-44.80%	-11.92%